@article{azzouzi:hal-01484971,
TITLE = {Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial},
AUTHOR = {Azzouzi, Abdel-Rahm{\`e}ne and Vincendeau, S{\'e}bastien and Barret, Eric and Cicco, Antony and Kleinclauss, Fran{\c c}ois and Poel, Henk G. van Der and Stief, Christian G. and Rassweiler, Jens and Salomon, Georg and Solsona, Eduardo and Alcaraz, Antonio and Tammela, Teuvo T. and Rosario, Derek J. and Gomez-Veiga, Francisco and Ahlgren, G{\"o}ran and Benzaghou, Fawzi and Gaillac, Bertrand and Amzal, Billy and Debruyne, Frans M. J. and Fromont, Ga{\"e}lle and Gratzke, Christian and Emberton, Mark},
URL = {https://univ-rennes.hal.science/hal-01484971},
JOURNAL = {Lancet Oncology},
PUBLISHER = {Elsevier},
VOLUME = {18},
NUMBER = {2},
PAGES = {181-191},
YEAR = {2017},
MONTH = Feb, DOI = {10.1016/S1470-2045(16)30661-1},
PDF = {https://univ-rennes.hal.science/hal-01484971/file/Azzouzi_Padeliporfin%20vascular-targeted.pdf},
HAL_ID = {hal-01484971},
HAL_VERSION = {v1},
}